News | April 21, 2015

First Irish Patient Treated for Prostate Cancer in Prague

Proton Therapy Center Czech uses seed markers for precise tumor targeting across five treatments

Proton Therapy Center Czech, John, Irish, U.K., prostate cancer

April 21, 2015 — The Proton Therapy Center in the Czech Republic treated its first Irish patient for prostate cancer beginning in mid-March.

The PTC is well known to the U.K. audience thanks to the story of the British boy Ashya King. Ashya’s parents chose Prague for his brain tumor treatment to ensure the lowest possible side effects. 

But from the U.K. it is mostly men in their fifties and sixties who come for the proton beam therapy in Prague. That's because proton therapy is highly beneficial for the major male problem of prostate cancer. 

John is 64. His family and background is in Ireland and he often still returns to his home country. He came to the U.K. to work, for more than 25 years, for the military forces.

"I was on active surveillance for 18 months back home but felt like I was awaiting something to happen“, said John, describing his feelings of uncertainty. "At that time, I came across the stories of British patients treated in Prague and sat down to read PTC websites and watch the great videos of the center, located in a city I always wanted to visit. Of course there was also the story of Ashya King in the British media. “ 

John did not hesitate and decided for himself. "I just rang the head nurse of my urologist and announced that I was going for proton therapy. I got a message that the urologist was fine with that." Getting all the medical reports took a bit longer than he had imagined – it was Christmas time. "Once I had my folder I sent it to PTC. There the patient manager called Lucie immediately got in touch. She was very supportive and in constant touch. “

John had never visited Prague although he had always wanted to. He and his wife were impressed. "I liked [the] center from day one”, he said. That was when he came for his first consultation and planning of computed tomography (CT) and magnetic resonance imaging (MRI) scans. Then he went back to the U.K. to get some things sorted and came back in mid-March to start his five sessions of treatment.

It consisted of five fractions only – a major advantage of proton beam therapy which enables higher doses onto the tumor, increasing the efficiency and minimizing the unwanted dose around the tumor. “In early stage cases of prostate cancer, PTC Czech has 97 percent curability and the data corresponds to the world clinical studies on proton therapy,” added Jiri Kubes, M.D., PTC medical director. This is also strengthened by the use of golden seeds – golden markers which help to target the beam even more precisely. These golden pellets are applied directly at PTC.

“So far I feel great,” said John.

For more information: www.proton-cancer-treament.com

Related Content

Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Overlay Init